rethinkPeptides Search
Menu
Study breakdown

Macrocyclic Inhibitors of the Blood Clotting Protease Plasmin

evidence
The takeaway

Macrocyclic inhibitors targeting the serine protease plasmin showed potent enzyme inhibition, advancing macrocyclic drug design for controlling excessive blood clot dissolution — relevant to bleeding disorders.

Key finding

Macrocyclic inhibitors targeting the serine protease plasmin showed potent enzyme inhibition, advancing macrocyclic drug design for controlling excess

What the researchers found

Macrocyclic inhibitors targeting the serine protease plasmin showed potent enzyme inhibition, advancing macrocyclic drug design for controlling excessive blood clot dissolution — relevant to bleeding disorders.

Why it matters

Relevant for peptide research.

How the study worked

research study.

What this study cannot tell us

See abstract.

How to read the evidence

emerging evidence.

When this study was published

Published in 2009.

The bigger picture

Advances peptide research.

Questions still open

  • Further research needed.

Common questions

What was studied?
Macrocyclic Inhibitors of the Blood Clotting Protease Plasmin
What was found?
Macrocyclic inhibitors targeting the serine protease plasmin showed potent enzyme inhibition, advancing macrocyclic drug design for controlling excessive blood clot dissolution — relevant to bleeding disorders.

Read the original research

Macrocyclic inhibitors for the serine protease plasmin.

Journal of enzyme inhibition and medicinal chemistry, 24(3), 779-94

Citation

Xue, Fengtian; Seto, Christopher T. (2009). Macrocyclic inhibitors for the serine protease plasmin.. Journal of enzyme inhibition and medicinal chemistry, 24(3), 779-94. https://doi.org/10.1080/14756360802364401